JCARH125
AssetAlso Orvacabtagene autoleucel
BCMA-directed chimeric antigen receptor (CAR) T-cell therapy targeting multiple myeloma cells
- Stage
- Phase 1
- Modality
- Cell therapy
- Target
- TNFRSF17
- 1
- Indication
- 122
- Trials
- 1
- Developer
Indications
1Multiple myeloma
Phase 1, Completed, NCT03430011, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Trials122
- Evidence for its targets2
- Competitors3
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.